USPTA And ACSM Announce Exercise Is Medicine(TM) Partnership The American College of Sports
Medicine (ACSM) announced a partnership with the United States Professional Tennis Association (USPTA) as it relates to two of the associations' initiatives: Exercise is
Medicine ? and Tennis - for the
health of it!, respectively. The announcement was made on Friday, May 9, during the free Tennis Across America? clinic, held in Houston.
Source: www.medicalnewstoday.comProstate Cancer Treatment Offers Results Without Side Effects Sanofi Aventis U.S. announced that the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) to include six-year overall survival analysis from the MOSAIC trial in the Eloxatin(R) (oxaliplatin injection) prescribing information (PI).
Source: www.medicalnewstoday.comPneumonia: There Are Ways To Avoid It! So Concludes A Major Multicentre Study Conducted In Spain Community-acquired pneumonia - in other words, pneumonia caught outside hospital - can be prevented, according to a Spanish report to be published in the forthcoming issue of the ERJ, the peer-reviewed scientific publication of the European Respiratory Society (ERS).
Source: www.medicalnewstoday.comEpstein-Barr Virus: An Infectious Cause For COPD? Terence McManus (Mater Hospital, Belfast, UK) and his colleagues examined the role of Epstein-Barr virus (EBV) in chronic obstructive pulmonary disease (COPD), the umbrella medical term used nowadays for bronchitis and emphysema. COPD is a common respiratory condition, for which smoking is the most frequently found risk factor.
Source: www.medicalnewstoday.comSNM Hosts 55th Annual Meeting Of Nuclear Medicine And Molecular Imaging Research June 14-18, 2008 SNM's 55th Annual Meeting, "Molecular Imaging: Build on the Past, Define the Future," will be held June 14-18, 2008, at the Ernest N. Morial Convention Center, New Orleans, La., with more than 4,000 of the world's leading experts in molecular imaging and therapy and nuclear
medicine attending.
Source: www.medicalnewstoday.comBiPar Sciences Expands Clinical Development Of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial In Uterine Cancer BiPar Sciences, Inc. announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company's DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.
Source: www.medicalnewstoday.comFDA Clears ExAblate Fertility Enhancement Study In Women With Uterine Fibroids InSightec Ltd. announced that the U.S.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 3:00 AM
